CellVec enters strategic partnership with Peter MacCallum Cancer Centre

The partnership will enable high-potential research on cancer immunotherapy in Asia Pacific.

CellVec announced its strategic partnership with Australia's Peter MacCallum Cancer Centre (Peter Mac) on 30 September.

Peter Mac haematologist Professor Simon Harrison noted the partnership with CellVec will underpin and enable a pipeline of high-potential research focused on developing the next generation of cancer immunotherapies in the Asia Pacific.

"Lentiviral vectors are a critical component in the generation of advanced cell and gene therapies such as CAR-T cells, but the complexity in manufacture impacts quality, cost, and accessibility. Our CellVec Vector Platform seeks to address this by ensuring optimal process performance from helper and packaging construct expression to upstream and downstream processes, producing high-quality products," said CellVec Chief Scientific Officer Dr. Lucas Chan.

Established in 2018 within the regional biotechnology hub of Singapore, CellVec was awarded GMP certification in 2020 by the Health Sciences Authority.